BioAge Labs, Inc.
BIOAFigures shown here come from public SEC filings. Dates beside each section show the available history.
How BioAge Labs, Inc. Makes Money
Follow each dollar of revenue through to what shareholders keep.
From revenue to net income
Pick a year or quarter. Each band's width is its dollar amount.
Financial Summary
Choose a year or quarter, compare it with the same period a year earlier, and open any row for its full filing history.
Loading financial history…
SEC filings supply these figures; updates after the dates shown are not included. This page includes 3 annual periods. The latest annual period ends Dec 31, 2025. The latest insider filing shown is dated Jun 12, 2026. The latest institutional report shown is dated Mar 31, 2026; other ownership filings may exist.
Ownership
Who holds the shares, as reported in SEC ownership filings.
Reported 13F positions
Each row shows what a filer reported for one date, not a current position. The link opens that filing.
| Filer | Report date | Shares | Value | Filing |
|---|---|---|---|---|
| Cornerstone Financial Management LLC | 2026-03-31 | 110 | $1.92K | SEC filing |
| PNC FINANCIAL SERVICES GROUP, INC. | 2026-03-31 | 2,073 | $36.3K | SEC filing |
| Stonepine Capital Management, LLC | 2026-03-31 | 50,000 | $875K | SEC filing |
| JPMORGAN CHASE & CO | 2026-03-31 | 173,570 | $2.75M | SEC filing |
| CITIGROUP INC | 2026-03-31 | 13,384 | $234K | SEC filing |
| Militia Capital Management LLC | 2026-03-31 | 32,286 | $565K | SEC filing |
| Russell Investments Group, Ltd. | 2026-03-31 | 63,256 | $1.11M | SEC filing |
| ANTIPODES PARTNERS Ltd | 2026-03-31 | 915 | $16K | SEC filing |
| IFP Advisors, Inc | 2026-03-31 | 9 | $157 | SEC filing |
| Tower Research Capital LLC (TRC) | 2026-03-31 | 2,872 | $50.2K | SEC filing |
| WEXFORD CAPITAL LP | 2026-03-31 | 25,765 | $451K | SEC filing |
| Pivotal bioVenture Partners Investment Advisor LLC | 2026-03-31 | 653,374 | $11.4M | SEC filing |
| Cormorant Asset Management, LP | 2026-03-31 | 2,890,605 | $50.6M | SEC filing |
| Polar Capital Holdings Plc | 2026-03-31 | 1,132,640 | $19.8M | SEC filing |
| ALLIANCEBERNSTEIN L.P. | 2026-03-31 | 29,000 | Not shown | SEC filing |
| MassMutual Private Wealth & Trust, FSB | 2026-03-31 | 165 | $2.89K | SEC filing |
| XTX Topco Ltd | 2026-03-31 | 46,878 | $820K | SEC filing |
| Mirae Asset Global Investments Co., Ltd. | 2026-03-31 | 2,265 | $39.6K | SEC filing |
| Y-Intercept (Hong Kong) Ltd | 2026-03-31 | 201,337 | $3.52M | SEC filing |
| SIMPLEX TRADING, LLC | 2026-03-31 | 2,322 | $40.6K | SEC filing |
- Each value is checked against BioAge Labs, Inc.'s share prices from within about three months of its report date (insiders' Form 4 trades and the latest close).
- Value not shown for 1 row: the value per share could not be confirmed against the share prices on file from within three months of the report date.
120 filers have only one report here.
Unusually large insider trades
Each trade is compared with the other insider trades of the same kind in the same security among BioAge Labs, Inc.'s recent filings on file. Size alone is context, not a prediction or evidence of improper trading.
- 2026-01-13 · Fortney Kristen: Larger than all 10 other insider sales of Common Stock on file. SEC filing
- 2025-12-04 · RUBIN PAUL D: Larger than 9 of the 10 other insider sales of Common Stock on file. SEC filing
Purchases & sales (open market or private)
| Security | Code | Price | Filing | |||
|---|---|---|---|---|---|---|
| 2026-04-01 | RUBIN PAUL D · Chief Medical Officer | Common Stock | S — Open market or private sale | −8,820 | 17.81 | SEC filing |
| 2026-03-02 | RUBIN PAUL D · Chief Medical Officer | Common Stock | S — Open market or private sale | −7,433 | 20.30 | SEC filing |
| 2026-02-02 | RUBIN PAUL D · Chief Medical Officer | Common Stock | S — Open market or private sale | −7,433 | 18.75 | SEC filing |
| 2026-01-13 | GOLDSTEIN DOV A MD · Chief Financial Officer | Common Stock | S — Open market or private sale | −4,440 | 19.45 | SEC filing |
| 2026-01-13 | GOLDSTEIN DOV A MD · Chief Financial Officer | Common Stock | S — Open market or private sale | −8,974 | 18.43 | SEC filing |
| 2026-01-13 | GOLDSTEIN DOV A MD · Chief Financial Officer | Common Stock | S — Open market or private sale | −11,663 | 20.54 | SEC filing |
| 2026-01-13 | GOLDSTEIN DOV A MD · Chief Financial Officer | Common Stock | S — Open market or private sale | −1,923 | 21.08 | SEC filing |
| 2026-01-13 | Fortney Kristen · Chief Executive Officer | Common Stock | S — Open market or private sale | −233,107 | 18.12 | SEC filing |
Showing 8 of 20 rows
Grants, exercises, tax & gifts
| Security | Code | Filing | |||
|---|---|---|---|---|---|
| 2026-06-10 | ENRIGHT PATRICK G · Director | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +22,000 | SEC filing |
| 2026-06-10 | Davidson Michael H. · Director | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +22,000 | SEC filing |
| 2026-06-10 | Pande Vijay Satyanand · Director | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +22,000 | SEC filing |
| 2026-06-10 | HEALY JAMES · Director | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +22,000 | SEC filing |
| 2026-06-10 | GARNIER JEAN PIERRE · Director | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +22,000 | SEC filing |
| 2026-06-10 | Hemrajani Rekha · Director | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +22,000 | SEC filing |
| 2026-04-23 | GOLDSTEIN DOV A MD · Chief Financial Officer | Stock Option (Right to Buy) | M — Exercise or conversion of derivative security | −3,542 | SEC filing |
| 2026-04-23 | GOLDSTEIN DOV A MD · Chief Financial Officer | Common Stock | M — Exercise or conversion of derivative security | +3,542 | SEC filing |
Showing 8 of 20 rows
These tables describe filed transactions, not current holdings. Prices are shown as filed; a currency is added only when the filing's data names one. Amended and possible duplicate rows are left out of size comparisons and transaction groups.